

#### **IBA Lifesciences GmbH**

Rudolf-Wissell-Str. 28 37079 Goettingen Germany

Tel.: +49 (0) 551-5 06 72-0 E-mail: info@iba-lifesciences.com

www.iba-lifesciences.com

## **Data Sheet**

# pDSG-IBA102

Cat. No.: 5-5219-001

Version: 3.0

Revision Date: 28.07.2021

Description	StarGate Acceptor Vector is a small transient expression vector especially developed for the use in combination with the MEXi mammalian expression system. In addition, it contains the human cytomegalovirus (CMV) immediate-early promoter for high-level expression and the origin of replication from Epstein-Barr Virus (oriP) for extrachromosomal replication driven by EBNA-1 expressed by MEXi-293E cells. The expressed recombinant protein will be secreted in the cell culture medium.			
Affinity tag	Twin-Strep-tag® is fused to the C-terminus of the recombinant protein.			
Secretion	BM40 secretory signal peptide is encoded for the transfer of the expressed protein into the medium. During the translocation the signal peptide is removed by endogenous proteases.			
Cloning Strategy	Cloning into StarGate Acceptor Vectors has to be done with the restriction enzyme Esp3I. There is no Multiple Cloning Site (MCS) available that can be used for the integration of the gene of interest instead (see manual).			
Resistance	Ampicillin: for selection of transformed E. coli cells			
Form	5 μg, dissolved in 20 μl TE buffer, pH 8.0: 10 mM Tris/HCl, 1 mM EDTA			
Concentration	250 ng/μl			
Stability	12 months after shipping			
Storage	recommended: 2-8 °C for frequent usage, -20 °C for long-term storage			
Shipping	room temperature			
Hazards	Product is not classified as hazardous according to (EC) No 1272/2008 [CLP].  A Material Safety Data Sheet is provided.			

#### For research use only


#### Trademark information


The owners of trademarks marked by """ or "TM" are identified at <a href="http://www.iba-lifesciences.com/patents.html">http://www.iba-lifesciences.com/patents.html</a>. Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

#### Important licensing information

This product is covered by intellectual property (IP) rights and on completion of the sale IBA Lifesciences grants respective Limited Use Label Licenses to purchaser. IP rights and Limited Use Label Licenses for said technology are further described and identified at <a href="http://www.iba-lifesciences.com/patents.html">http://www.iba-lifesciences.com/patents.html</a> or upon inquiry at <a href="mailto:info@iba-lifesciences.com">info@iba-lifesciences.com</a> or at IBA Lifesciences GmbH, Rudolf-Wissell-Str. 28, 37079 Goettingen, Germany. By use of this product the purchaser accepts the terms and conditions of all applicable Limited Use Label Licenses.

### **Expression cassette of pDSG-IBA102**





Features	from bp	to bp	Sequencing primer
polyA signal sequence	1	213	ESG/CSG-Primer-for
pUC ori origin	222	836	
Ampicillin resistance gene	999	1856	5'- GAGAACCCACTGCTTACTGGC -3'
oriP, episomal replication origin	2021	3996	
CMV promoter	4277	4864	ESG/CSG-Primer-rev
forward primer binding site	4877	4897	
BM40 signal sequence	4941	4994	5'- TAGAAGGCACAGTCGAGG -3'
LacZ alpha fragment	5222	5623	
Twin-Strep-tag®	5687	5779	]
reverse primer binding site	5841	5858	
total vector length		5858	